Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $114.31 billion, has established itself as a dominant force in the treatment ...

Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at any time, the Boston-based ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceuticals has ...

As a company, Vertex says, “We strike at the core of serious diseases to change people’s lives. Bringing together the ...

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. The company tends to run up after significant price drops. Vertex's business and prospects remain attractive. However ...

Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to ...

VERTEX PHARMACEUTICALS insiders have traded $VRTX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been ...